Abstracts tagged "meta-analysis and systemic sclerosis"

Abstract Number: 1894 • 2015 ACR/ARHP Annual Meeting
Calcium Channel Blockers Are More Effective in the Treatment of Primary Raynaud’s Phenomenon Compared to Secondary: A Meta-Analyis
Janet E. Pope¹, Fadumo Rirash², Paul Tingey³, Sarah Harding⁴, Lara J. Maxwell⁵, Peter Tugwell⁶, Jordi Pardo⁷, Elizabeth Ghogomu⁸ and George A. Wells⁹, ¹University of Western Ontario, London, ON, Canada, ²Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ³Faculty of Medicine, University of Queensland, Brisbane, Australia, ⁴ERLanger, ERLanger, KY, ⁵Centre for Global Health, Institute of Population Health, University of Ottawa, Ottawa, ON, Canada, ⁶Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Ottawa, Cochrane Musculoskeletal Group, Ottawa, ON, Canada, ⁹Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose: To assess the benefits and harms of calcium channel blockers (CCBs) versus placebo for the treatment of Raynaud's phenomenon (RP) comparing primary to secondary…
Abstract Number: 2977 • 2015 ACR/ARHP Annual Meeting
A Meta-Analysis of Phosphodiesterase 5 Inhibitors for the Treatment of Raynaud’s Phenomenon
Janet E. Pope¹, Fadumo Rirash², Paul Tingey³, Sarah Harding⁴, Lara J. Maxwell⁵, Jordi Pardo⁶, Elizabeth Ghogomu⁷, Peter Tugwell⁸ and George A. Wells⁹, ¹University of Western Ontario, London, ON, Canada, ²Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ³Faculty of Medicine, University of Queensland, Brisbane, Australia, ⁴ERLanger, ERLanger, KY, ⁵Centre for Global Health, Institute of Population Health, University of Ottawa, Ottawa, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷University of Ottawa, Cochrane Musculoskeletal Group, Ottawa, ON, Canada, ⁸Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ⁹Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose: To assess the benefits and harms of phosphodiesterase 5 inhibitors (PDE5) for the treatment of Raynaud's phenomenon (RP).Methods: The Cochrane library, MEDLINE, EMBASE and Clinicaltrials.gov…
Abstract Number: 2700 • 2014 ACR/ARHP Annual Meeting
Clinical Phenotype of Systemic Sclerosis Patients with Anti-RNA Polymerase III Antibodies: A New French Cohort, Systematic Review and Meta-Analysis
Vincent Sobanski^1,2, Luc Dauchet^3,4, Guillaume Lefèvre², Marc Lambert⁵, Sandrine Morell-Dubois⁶, Thierno Sy⁶, Eric Hachulla¹, Pierre-Yves Hatron⁷, Sylvain Dubucquoi^8,9 and David Launay^1,9, ¹Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²EA 2686, Lille, LILLE, France, ³Service d'Epidémiologie Régionale, CHRU Lille, LILLE, France, ⁴INSERM U744, LILLE, France, ⁵Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁶Internal Medicine, CHRU Lille, LILLE, France, ⁷Internal Medicine, Lille, France, ⁸Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁹EA 2686, Lille, Lille, France
Background/Purpose: Anti-RNA polymerase III antibodies (anti-RNAP III) are one of the most frequent antinuclear antibodies identified in systemic sclerosis (SSc), with an estimated prevalence of…
Abstract Number: 726 • 2014 ACR/ARHP Annual Meeting
Risk of Ischemic Stroke in Patients with Systemic Sclerosis: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Praveen Ratanasrimetha², Charat Thongprayoon³, Wisit Cheungpasitporn³ and Promporn Suksaranjit⁴, ¹Department of Internal medicine, Bassett medical center, Cooperstown, NY, ²Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ³Department of Medicine, Mayo clinic, Rochester, MN, ⁴Department of Cardiology, University of Utah School of Medicine, Salt Lake City, UT
Risk of Ischemic Stroke in Patients with Systemic Sclerosis: A Systematic Review and Meta-analysisBackground/Purpose: Several chronic inflammatory disorders, such as rheumatoid arthritis and systemic lupus…
Abstract Number: 707 • 2012 ACR/ARHP Annual Meeting
Risk of Cancer in Systemic Sclerosis: Meta-Analysis of Population-Based Cohort Studies
Akira Onishi¹, Daisuke Sugiyama², Akio Morinobu³ and Shunichi Kumagai⁴, ¹Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Center of Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: The risk of cancer compared with general population has been elevated in several connective tissue diseases. However, the standardized incidence ratios (SIRs) for overall…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].